Skip to content
Proteolix logo — Biopharmaceutical company engaged in the development and com...

Proteolix

Biopharmaceutical company engaged in the development and commercialization of innovative therapies

Founded 2003 United States United States 12 employees Series C Total: $142.30M Biopharma, Biotechnology +2

General Information

Company Name Proteolix
Founded Year 2003
Location United States United States
Employees 12
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Proteolix. To contact Proteolix, visit proteolix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Proteolix compare?

A PDF of Proteolix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Proteolix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Proteolix

Proteolix, a biopharmaceutical company founded in 2003, has established itself as a pioneer in the development and commercialization of innovative therapies targeting cancers and immunological conditions. Based in South San Francisco, United States, the company focuses on disrupting protein turnover in cells by inhibiting the proteasome.

Their leading product candidate, carfilzomib (PR-171), is administered intravenously and undergoing multiple clinical trials to test its safety and efficacy across various cancer types. In addition to this, Proteolix is advancing a pipeline of next-generation proteasome inhibitors, including oral and selective immunoproteasome inhibitors, aiming to broaden the therapeutic applications of this novel target class.

Having secured a substantial $79.00M Series C investment on 01 September 2008, the company is backed by stalwart investors such as US Venture Partners, Advanced Technology Ventures, Delphi Ventures, and The Vertical Group, among others. This funding supports their continued research and development efforts, positioning Proteolix for potential breakthroughs in cancer treatment.

Business keywords: biopharmaceutical, proteasome inhibitors, cancer treatment, carfilzomib, PR-171, clinical trials, immunological conditions, protein turnover disruption, oral proteasome inhibitors, immunoproteasome inhibitor, therapeutic development, South San Francisco, intravenous administration, pharmaceutical commercialization

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $79.00M 7
US Venture Partners, Advanced Technology Ventures +5
01 Sep 2008
Series B $45.00M 1
Delphi Ventures
01 Jun 2006
Series A $18.30M -
01 Dec 2003

Proteolix Alternatives & Competitors

View All Alternatives
Proteolix vs

Dedicated to advancing cancer treatment through innovative MEK kinase inhibitors.

Pre-Seed
1 employees
Biotechnology, Health and Wellness
Proteolix vs

A late-stage clinical biopharmaceutical company focused on developing novel therapies for a range of...

Post-IPO Equity
18 employees
Biopharma, Biotechnology
Proteolix vs

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care

FAQ About Proteolix

Biopharmaceutical company engaged in the development and commercialization of innovative therapies
Proteolix was founded in 2003.
Proteolix is headquartered in United States.
Proteolix operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical, proteasome inhibitors, cancer treatment and carfilzomib.
Proteolix has approximately 12 employees.
Proteolix has completed 3 funding rounds, raising a total of $142.30M. The latest funding stage is Series C.
Top alternatives and competitors to Proteolix include AlloMek Therapeutics LLC, SELLAS Life Sciences Group, Inc., Entero Therapeutics (Nasdaq: ENTO), Cascadian Therapeutics, Inc., Ambit. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Proteolix and AlloMek Therapeutics LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Proteolix, https://www.bouncewatch.com/company/proteolix, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout